Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 9 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT00681044 |
| HD Melphalan and SCT in Patients With IGDD or LCDD |
| terminated |
| Phase 2 |
| 5 |
| Boston Medical CenterOTHER |
| 1 |
| Apr 28, 2017 |
| clinicaltrials |
| NCT01194791 | Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed(LENDEXAL) | completed | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02802163 | Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Apr 25, 2017 | clinicaltrials |
| NCT00109889 | S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 24, 2017 | clinicaltrials |
| NCT01884688 | UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma | completed | Phase 2 | 3 | University of ArkansasOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT01351623 | Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 44 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT03105596 | Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) | unknown | Phase 2 | 46 | Peking UniversityOTHER | 0 | Apr 11, 2017 | clinicaltrials |
| NCT01004991 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders(MINI HEME) | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 0 | Apr 6, 2017 | clinicaltrials |
| NCT01323751 | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma(ACY-1215) | completed | Phase 1 / Phase 2 | 120 | CelgeneINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01534143 | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 1 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT01207765 | Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma | terminated | Phase 2 | 8 | Tufts Medical CenterOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT00259740 | Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab | completed | Phase 2 | 96 | AmgenINDUSTRY | 0 | Mar 15, 2017 | clinicaltrials |
| NCT01484314 | Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia(VISMOLY) | terminated | Phase 2 | 31 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT00577642 | Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates | completed | Phase 2 | 29 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00600353 | Multi-day Doses in Prevention of Nausea and Emesis | completed | Phase 2 | 20 | University of Kansas Medical CenterOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01181271 | Tandem Auto-Allo Transplant for Lymphoma | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00143845 | Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant | completed | Phase 2 | 54 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 8, 2017 | clinicaltrials |
| NCT00307086 | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT03069248 | Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon | completed | Phase 2 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00091260 | CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 82 | Vaishali SanchorawalaOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00679367 | Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis(MRD) | completed | Phase 2 | 16 | Boston Medical CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01019174 | Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma(MM_LEN_DEX_CY) | completed | Phase 1 / Phase 2 | 40 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00193973 | Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | completed | Phase 2 | 20 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Feb 17, 2017 | clinicaltrials |
| NCT02435108 | A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy | completed | Phase 2 | 2 | Samsung Medical CenterOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT02254551 | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | SCRI Development Innovations, LLCOTHER | 1 | Feb 16, 2017 | clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02402725 | A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma(UltraDex) | withdrawn | Phase 2 | 0 | Boston Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02955628 | RICE-ibrutinib in Relapsed DLBCL | unknown | Phase 2 | 34 | Singapore General HospitalOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02519114 | Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Maastricht University Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00143065 | Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00201682 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 36 | John ByrdOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT02113007 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma | terminated | Phase 2 | 2 | SCRI Development Innovations, LLCOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00790647 | Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 10 | Boston Medical CenterOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01029054 | Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT01389076 | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT00075608 | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | terminated | Phase 2 | 12 | Boston Medical CenterOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT02169180 | Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 16 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT02578121 | UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | terminated | Phase 2 | 5 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2017 | clinicaltrials |
Data updated 23 days agoSource updated May 2, 2017source: clinicaltrials